undefinedCentella Asiatica Extract

Mustafa Balevi,MD · Phase 1 active Small molecule

undefinedCentella Asiatica Extract is a Small molecule drug developed by Mustafa Balevi,MD. It is currently in Phase 1 development. Also known as: centella asiatica extract.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

• Baseline phase 1 → approval rate +9.6pp
  Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	undefinedCentella Asiatica Extract
Also known as	centella asiatica extract
Sponsor	Mustafa Balevi,MD
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• The Effect of Centella Asiatica Cream on Scar Tenderness Who Underwent Open Carpal Tunnel Release Surgery (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• undefinedCentella Asiatica Extract CI brief — competitive landscape report
• undefinedCentella Asiatica Extract updates RSS · CI watch RSS
• Mustafa Balevi,MD portfolio CI

Frequently asked questions about undefinedCentella Asiatica Extract

What is undefinedCentella Asiatica Extract?

undefinedCentella Asiatica Extract is a Small molecule drug developed by Mustafa Balevi,MD.

Who makes undefinedCentella Asiatica Extract?

undefinedCentella Asiatica Extract is developed by Mustafa Balevi,MD (see full Mustafa Balevi,MD pipeline at /company/mustafa-balevi-md).

Is undefinedCentella Asiatica Extract also known as anything else?

undefinedCentella Asiatica Extract is also known as centella asiatica extract.

What development phase is undefinedCentella Asiatica Extract in?

undefinedCentella Asiatica Extract is in Phase 1.

Related

• Manufacturer: Mustafa Balevi,MD — full pipeline
• Also known as: centella asiatica extract